Complete Genomics unveils DNBSEQ-T1+ and DNBSEQ-E25 Flash at AGBT 2025 General Meeting
MARCO ISLAND, Fla., Feb. 24, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today unveiled its latest high-performance sequencing solutions at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting. The newly introduced DNBSEQ-T1+* and DNBSEQ-E25 Flash* are designed to deliver speed, flexibility, and efficiency, empowering researchers with faster, high-quality genomic data. DNBSEQ-T1+: Mid-Throughput...
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 23, 2025, announced that the company is fully deploying the DeepSeek large model and promoting the application of DeepSeek R1 version across all business scenarios through localized strategies, achieving cost reduction, quality improvement, and efficiency enhancement throughout...
MGI Tech Closes Strategic Partnership with Oncoclínicas&Co to Contribute to Genomic Innovation in Oncological Health
Agreement contributes to expanding access to cutting-edge genomic technologies and improving diagnostic efficacy SÃO PAULO, Feb. 24, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, established a partnership with Oncoclínicas&Co, through OC Medicina de Precisão, which comprises Genomics, Pathology...
Fangzhou Inc. Announces Inclusion as a Constituent of the Hang Seng Composite Index
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company has been selected and will be included as a constituent of the Hang Seng Composite Index by Hang Seng Indexes Company Limited, with effect from March...
NMPA Accepts NDA and Grants Priority Review Designation to Innovent’s Ipilimumab Injection, China’s First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for ipilimumab injection (anti-CTLA-4 monoclonal antibody; R&D Code: IBI310) has been...
Review and Outlook of Sanyou Bio Intelligent Super-trillion Molecule Discovery Platform
SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- On February 15, 2025, Sanyou Bio conducted a full review of its Intelligent Super-trillion Molecule Discovery Platform. As the core technology of the platform, the intelligent super-trillion molecule library boasts a library capacity of up to 10 trillion, enabling the screening and identification of hundreds to thousands of lead molecules for a single target....
Over 3.2 million likes! Witsbb’s Australia Traceability Livestream Witnesses Quality Commitment, Allergen-Free Nutrition Gains Global Attention
SYDNEY, Feb. 23, 2025 /PRNewswire/ -- After travelling over ten hours by plane, Chinese well-known blogger @Guo Xiaopang Couple reached Sydney, Australia, and started Witsbb's traceability livestream, revealing the secrets behind its "allergen-free" nutrition. They demonstrated the brand's commitment to quality and transparency by livestreaming Witsbb's research capabilities and production chain. Winning over 3.2 million likes, the livestream triggered a...
Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10
SHANGHAI, Feb. 21, 2025 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued collaboration with Mabgeek in advancing MG-K10, a potential Best-in-Class therapy, a novel IL-4Rα-targeting antibody drug for atopic dermatitis and asthma, into U.S. Phase III trials. Mabgeek had a successful...
Coreline Soft Leads AI Medical Imaging Innovation at STR 2025
Introducing the AVIEW lineup specialized in simultaneous diagnosis and analysis of thoracic diseases Participating in HIMSS on March 3rd and completing HIPAA certification HUNTINGTON BEACH, Calif. and SEOUL, South Korea, Feb. 21, 2025 /PRNewswire/ -- Coreline Soft will demonstrate its cutting-edge AI-based lung and thoracic imaging solution lineup at the Society...
Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer
HONG KONG, Feb. 21, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of ivonescimab in combination with chemotherapy for first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) (HARMONi-BC1/AK112-308). Ivonescimab is a first-in-class PD-1/VEGF bispecific...
